Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dyne Therapeutics (DYN – Research Report), Biohaven Ltd. (BHVN – Research Report) and Teladoc (TDOC – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dyne Therapeutics (DYN)
Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Dyne Therapeutics yesterday and set a price target of $47.00. The company’s shares closed last Monday at $17.69.
According to TipRanks.com, Ulz is a 3-star analyst with an average return of
Dyne Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $41.63, which is a 172.6% upside from current levels. In a report issued on March 2, RBC Capital also maintained a Buy rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Biohaven Ltd. (BHVN)
In a report released today, Corinne Johnson from Goldman Sachs maintained a Buy rating on Biohaven Ltd., with a price target of $27.00. The company’s shares closed last Monday at $10.21.
According to TipRanks.com, Johnson is a 4-star analyst with an average return of
Currently, the analyst consensus on Biohaven Ltd. is a Moderate Buy with an average price target of $18.50, which is a 55.6% upside from current levels. In a report issued on February 23, Piper Sandler also maintained a Buy rating on the stock with a $30.00 price target.
Teladoc (TDOC)
BTIG analyst David Larsen maintained a Hold rating on Teladoc today. The company’s shares closed last Monday at $5.30.
According to TipRanks.com, Larsen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $7.22, implying a 44.1% upside from current levels. In a report issued on February 25, William Blair also maintained a Hold rating on the stock.
